Netherton Syndrome - Pipeline Insight, 2024

This “Netherton Syndrome - Pipeline Insight, 2024,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Netherton Syndrome Understanding

Netherton Syndrome: Overview

Netherton Syndrome is a rare disorder that is inherited as an autosomal recessive trait. The disorder is caused due to the mutation in the SPINK5 gene located on chromosome 5 which is responsible for encoding proteins that serve as the break on the activity of certain proteases in the skin protein. This disorder mainly affects the immune system, skin, and hair of an individual and is characterized by elevated IgE levels, scaling skin, hair anomalies, and increased susceptibility to atopic eczema. The syndrome is estimated to affect 1 in 200,000 newborn.

Netherton Syndrome - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Netherton Syndrome pipeline landscape is provided which includes the disease overview and Netherton Syndrome treatment guidelines. The assessment part of the report embraces, in depth Netherton Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Netherton Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Netherton Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Netherton Syndrome.

Netherton Syndrome Emerging Drugs Chapters

This segment of the Netherton Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Netherton Syndrome Emerging Drugs

LM 030: NovartisNovartis’ new drug candidate, LM 030, is a clinical stage ointment for the treatment of Netherton syndrome. The drug in its early clinical phases has demonstrated good safety and efficacy. The drug is a Kallikrein-related peptidase inhibitor. The drug has been designated with orphan drug status and has recently received fast track designation.

Isotretinoin: Timber PharmaceuticalsTimber Pharmaceuticals “breakthrough” drug Isotretinoin is currently being evaluated for the treatment of Netherton syndrome and has demonstrated good efficacy and tolerability in phase I trial. Isotretinoin is a keratolytics small molecule that inhibits sebaceous gland function and keratinization

Netherton Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Netherton Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Netherton Syndrome

There are approx. 6+ key companies which are developing the therapies for Netherton Syndrome. The companies which have their Netherton Syndrome drug candidates in the most advanced stage, i.e. phase II/III include, Novartis.

Phases

This report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase II/III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Netherton Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Netherton Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Netherton Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Netherton Syndrome drugs.

Netherton Syndrome Report Insights

• Netherton Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Netherton Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Netherton Syndrome drugs?
• How many Netherton Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Netherton Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Netherton Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Netherton Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• Timber pharmaceuticals
• Bridge Biopharma
• Evotec AG
• Dermelix Biotherapeutics
• Krystal Biotech

Key Products

• LM030
• Isotretinoin
• BBP 561
• LAB 150
• DMX 102
• KB-104

This product will be delivered within 2 business days.